Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Drug Metab ; 20(12): 958-966, 2019.
Article in English | MEDLINE | ID: mdl-31755384

ABSTRACT

BACKGROUND: The introduction of Monoclonal Antibodies (mAbs) and small-molecule Tyrosine Kinase Inhibitors (TKIs) that target the Epidermal Growth Factor Receptor (EGFR), marks a huge step forward in the Pancreatic Cancer (PC) therapy. However, anti-EGFR therapy is found to be successful only in a fraction of patients. Although anti-EGFR agents have shown considerable clinical promise, a serious adverse event associated with anti- EGFR therapy has been challenging. At this juncture, there is still more to be done in the search for effective predictive markers with therapeutic applicability. METHODS: A focused literature search was conducted to summarize the existing evidence on anti-EGFR agents in pancreatic cancer therapy. RESULTS: This review discusses various anti-EGFR agents currently in use for PC therapy and potential adverse effects associated with it. Existing evidence on EGFR TKIs demonstrated better tolerant effects and outcomes with multiple toxic regimens. Anti-EGFR therapy in combination with chemotherapy is necessary to achieve the best clinical outcomes. CONCLUSION: Future prospective studies on the identification of additional biological agents and novel anti-EGFR agents are warranted.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Pancreatic Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Antibodies, Monoclonal/adverse effects , ErbB Receptors/antagonists & inhibitors , Humans , Protein Kinase Inhibitors/adverse effects
2.
Hemoglobin ; 42(2): 84-90, 2018 Mar.
Article in English | MEDLINE | ID: mdl-30200838

ABSTRACT

Hemoglobinopathies evolved as a protective mechanism against malaria, which exhibit selective advantage in the heterozygous state. However, in a homozygous recessive condition, it poses a serious socioeconomic burden. Sickle cell anemia is an autosomal recessive hemoglobinopathy associated with erythrocytes sickling, vaso-occlusive crisis (VOC), as well as multi-organ failure and death. The coinheritance of other hemoglobinopathies is known to substantially modulate the clinical manifestation of sickle cell anemia. In the present study, we aimed to analyze the coinheritance of ß-thalassemia (ß-thal) in Hb S (HBB: c.20A>T) patients. The study includes 918 sickle cell anemia patients from 10 ethnic populations of Chhattisgarh State, India. Complete blood counts (CBCs) and hemoglobin (Hb) high performance liquid chromatography (HPLC) fractionation data were collected from patient record books. We observed Hb S-ß-thal in all the analyzed populations. Interestingly, high frequencies of Hb S-ß-thal have been observed in Satnami (53.8%), Rawat (47.1%), Gond (35.1%) and Panika (30.6%) populations. Inter-population comparison of hematological parameters [Hb F (p < 0.001), Hb A2 (p < 0.001), Hb (p = 0.03) and red blood cell distribution width (RDW) (p < 0.001)] revealed significant differences. We also observed that mean Hb F levels were significantly higher in Hb S compared to Hb S-ß-thal patients in the respective populations. Our study highlights the higher prevalence of ß-thal as well as the compound heterozygosity for Hb S and ß-thal in various populations of Chhattisgarh State, India.


Subject(s)
Anemia, Sickle Cell/genetics , Hemoglobin, Sickle/genetics , Heterozygote , beta-Thalassemia/genetics , Fetal Hemoglobin/analysis , Hemoglobin, Sickle/analysis , Humans , India/epidemiology , beta-Thalassemia/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...